McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Erin Wright from Morgan Stanley maintained a Buy rating on the stock and has a $745.00 price target.
Erin Wright has given his Buy rating due to a combination of factors that highlight McKesson’s strong performance and future potential. The company has reaffirmed its long-term guidance of 12-14% EPS growth, with expectations that the FY26 EPS could slightly exceed this range, driven by robust momentum in its Core US Pharma segment. This segment has consistently outperformed long-term targets, providing a solid foundation for future growth.
Additionally, McKesson is positioned well within the drug distribution industry, which is experiencing a “golden era” characterized by growth, stable margins, and regulatory insulation. The company’s focus on US Pharma strength is expected to support EPS above long-term targets, despite a potentially conservative initial guidance. Overall, McKesson’s strong fundamentals and strategic positioning make it a top pick in the current market environment.